Aurobindo Pharma: Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana
Aurobindo Pharma (AUROPHARMA) filed a disclosure titled "Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana". The company is valued at about ₹97,682 crore.
What happened
Aurobindo Pharma (AUROPHARMA) filed a disclosure with the exchanges on 29 September 2026 at 04:45 PM titled "Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana".
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹97,682 crore.
The stock last traded at ₹1,697.7, against a 52-week range of ₹1,066.8–₹1,740 (2.4% below the high).
Before this filing the shares had moved +3.1% over the month and +9.2% over three months. Average daily turnover over the last 20 sessions was about ₹119 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
BCEIE has no earlier regulatory filing from this company on record since May 2026.
Across 150 similar disclosures by other Healthcare companies, shares moved +0.3% on average the next day and +1.3% over five days; 47% of them rose the next day.
Market-wide, 5,432 regulatory filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
- AUROPHARMA Outlook for the Week (September 28, 2026 – October 02, 2026)
- Aurobindo Pharma stock in focus after subsidiary Unit-IV receives VAI status from US FDA
- Aurobindo Pharma shares fall 2% after USFDA issues one observation for Telangana facility
- Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speci
- Aurobindo Pharma Unit-VII Receives US FDA Voluntary Action Indicated Classification
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.